文献速递血栓与止血造血干细胞移植与细胞治疗

慢病毒转导与转基因小鼠中内皮细胞表达意外增强FVIII免疫原性

Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice.
PubMed 文献 · Blood Adv · 2020-01-01

在血友病A小鼠中,通过慢病毒原位转导(T2F8LV)或胚胎干细胞介导的转基因(T2F8Tg)使内皮细胞表达FVIII,两种方式均引发强烈免疫反应;T2F8LV小鼠全部产生抑制物且血浆FVIII检测不到,T2F8Tg小鼠血浆FVIII正常但免疫后产生高滴度抑制物。内皮细胞表达MHCII并可作为辅助抗原提呈细胞向Tfh细胞提呈FVIII。

要点

  • 内皮细胞特异性表达FVIII的两种小鼠模型均出现强烈免疫反应。
  • T2F8LV原位转导后所有FVIIInull小鼠产生抑制物,血浆FVIII检测不到。
  • T2F8Tg小鼠血浆FVIII正常,但免疫后抑制物高滴度、FVIII降至检测不到。

核心结论

  • 内皮细胞表达的FVIII具有未预料的免疫原性,提示内皮细胞作为辅助APC向Tfh细胞提呈FVIII,在抑制物调控中可能起情境依赖性作用。

研究设计与样本

  • 在血友病A小鼠(FVIIInull)中,采用Tie2启动子驱动FVIII表达,通过慢病毒原位转导(T2F8LV)或胚胎干细胞介导的转基因(T2F8Tg)两种方式使内皮细胞表达FVIII。

主要发现

  • T2F8LV原位转导后,所有FVIIInull小鼠均产生抑制物,血浆FVIII检测不到。
  • T2F8Tg小鼠血浆FVIII水平正常,但对FVIII免疫应答敏感;单次注射FVIII加不完全弗氏佐剂后产生高滴度抑制物,血浆FVIII降至检测不到。
  • 小鼠和人内皮细胞均表达MHCII,并在体外有效结合和摄取FVIII蛋白。
  • 经炎症细胞因子体外预处理的内皮细胞可将外源性摄取的FVIII功能性提呈给先前致敏的CD4+/CXCR5+ Tfh细胞,驱动FVIII特异性增殖。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Factor VIII (FVIII) replacement therapy for hemophilia A is complicated by development of inhibitory antibodies (inhibitors) in ∼30% of patients. Because endothelial cells (ECs) are the primary physiologic expression site, we probed the therapeutic potential of genetically restoring FVIII expression selectively in ECs in hemophilia A mice (FVIIInull). Expression of FVIII was driven by the Tie2 promoter in the context of lentivirus (LV)-mediated in situ transduction (T2F8LV) or embryonic stem cell-mediated transgenesis (T2F8Tg). Both endothelial expression approaches were associated with a strikingly robust immune response. Following in situ T2F8LV-mediated EC transduction, all FVIIInull mice developed inhibitors but had no detectable plasma FVIII. In the transgenic approach, the T2F8Tg mice had normalized plasma FVIII levels, but showed strong sensitivity to developing an FVIII immune response upon FVIII immunization. A single injection of FVIII with incomplete Freund adjuvant led to high titers of inhibitors and reduction of plasma FVIII to undetectable levels. Because ECs are putative major histocompatibility complex class II (MHCII)-expressing nonhematopoietic, "semiprofessional" antigen-presenting cells (APCs), we asked whether they might directly influence the FVIII immune responses. Imaging and flow cytometric studies confirmed that both murine and human ECs express MHCII and efficiently bind and take up FVIII protein in vitro. Moreover, microvascular ECs preconditioned ex vivo with inflammatory cytokines could functionally present exogenously taken-up FVIII to previously primed CD4+/CXCR5+ T follicular helper (Tfh) cells to drive FVIII-specific proliferation. Our results show an unanticipated immunogenicity of EC-expressed FVIII and suggest a context-dependent role for ECs in the regulation of inhibitors as auxiliary APCs for Tfh cells.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shi Q, Carman CV, Chen Y, et al. Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice. Blood Adv. 2020. PMID: 32453842. doi:10.1182/bloodadvances.2020001468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。